Approval · Notice of Compliance 27034 · 2021
JAMP-RISPERIDONE: Notice of Compliance 27034
Issued November 15, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27034
- Date
- November 15, 2021
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Updating the Product Monograph
- Canadian reference product
- RISPERDAL (Janssen Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JAMP-RISPERIDONE | Not yet assigned | — |
Medicinal ingredients
- RISPERIDONE TARTRATE 1 MG per ML